Cosmo Pharmaceuticals Overview
- Year Founded
-
1997
- Status
-
Public
- Employees
-
339
- Stock Symbol
-
COPN
- Investments
-
6
- Share Price
-
$71.16
- (As of Friday Closing)
Cosmo Pharmaceuticals General Information
Description
Cosmo Pharmaceuticals NV is a pharmaceutical company with a focus on gastrointestinal diseases, dermatology and healthtech. The company develops and manufactures products that are distributed globally by its partners. Products that the company has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers' diarrhoea (TD) and Winlevi for the treatment of acne. Product pipeline includes Breezula, GI Genius, Methylene blue MMX, Aemcolo, CB-03-10 and CB-01-33.
Contact Information
Website
www.cosmopharma.comCorporate Office
- Riverside II
- Sir John Rogerson's Quay
- Dublin 2
- Ireland
Corporate Office
- Riverside II
- Sir John Rogerson's Quay
- Dublin 2
- Ireland
Cosmo Pharmaceuticals Stock Performance
As of 14-Feb-2025, Cosmo Pharmaceuticals’s stock price is $71.16. Its current market cap is $1.14B with 16M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $71.16 | $70.39 | $64.65 - $95.16 | $1.14B | 16M | 16.4K | $4.67 |
Cosmo Pharmaceuticals Financials Summary
As of 30-Jun-2024, Cosmo Pharmaceuticals has a trailing 12-month revenue of $201M.
|
In Thousands, USD |
TTM 30-Jun-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 1,205,590 | 926,883 | 1,043,752 | 1,166,680 |
| Revenue | 200,539 | 100,395 | 107,337 | 76,937 |
| EBITDA | 110,145 | 21,913 | 46,837 | 44,100 |
| Net Income | 75,272 | (5,337) | 18,110 | 25,623 |
| Total Assets | 684,144 | 612,369 | 814,585 | 912,074 |
| Total Debt | 1,560 | 2,033 | 186,166 | 192,384 |
Cosmo Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Cosmo Pharmaceuticals Comparisons
Industry
Financing
Details
Cosmo Pharmaceuticals Competitors (26)
One of Cosmo Pharmaceuticals’s 26 competitors is Spear Pharmaceuticals, a Formerly PE-Backed company based in Fort Myers, FL.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Spear Pharmaceuticals | Formerly PE-Backed | Fort Myers, FL | ||||
| Regeneron Pharmaceuticals | Formerly VC-backed | Tarrytown, NY | ||||
| VYNE Therapeutics | Formerly VC-backed | Bridgewater, NJ | ||||
| Botanix Pharmaceuticals | Corporation | West Perth, Australia | ||||
| Pfizer Manufacturing Austria | Corporation | Orth An Der Donau, Austria |
Cosmo Pharmaceuticals Patents
Cosmo Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-2453243-A1 | Method for the diagnosis and/or follow up of the evolution of a tumor | Inactive | 11-Nov-2010 | ||
| US-20220280531-A1 | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives | Active | 03-Aug-2007 | ||
| JP-2013163683-A | Enzymatic process for obtaining 17α-monoester of cortexolone and/or its 9,11-dehydroderivative | Active | 03-Aug-2007 | ||
| ES-2462946-T3 | Enzymatic process to obtain 17-alpha cortexolone propionate in crystalline form iii | Active | 03-Aug-2007 | ||
| US-20230104965-A1 | Enzymatic process for obtaining 17 alpha-monoesters of cortexolone and/or its 9,11-dehydroderivatives | Pending | 03-Aug-2007 | C07J5/0053 |
Cosmo Pharmaceuticals Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Cosmo Pharmaceuticals Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Cosmo Pharmaceuticals Investments & Acquisitions (6)
Cosmo Pharmaceuticals’s most recent deal was a Merger/Acquisition with Cassiopea for . The deal was made on 17-Dec-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Cassiopea | 17-Dec-2021 | Merger/Acquisition | Pharmaceuticals | ||
| Acacia Pharma | 02-Jan-2020 | PIPE | Pharmaceuticals | ||
| Paion | 27-Jun-2016 | PIPE | Pharmaceuticals | ||
| BioMAS | 11-Mar-2014 | Corporate | Biotechnology | ||
| AIMM Therapeutics | 07-Jun-2013 | Later Stage VC | Drug Discovery |
Cosmo Pharmaceuticals ESG
Risk Overview
Risk Rating
Updated May, 31, 2024
29.37 | Med Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,120
Rank
Percentile
Pharmaceuticals
Industry
of 853
Rank
Percentile
Pharmaceuticals
Subindustry
of 425
Rank
Percentile
Cosmo Pharmaceuticals Exits (3)
Cosmo Pharmaceuticals’s most recent exit was on 02-Jan-2020 from Acacia Pharma. The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Acacia Pharma | 02-Jan-2020 | Completed |
|
||
| Paion | 27-Jun-2016 | Completed |
|
||
| AIMM Therapeutics | 07-Jun-2013 | Later Stage VC | Completed |
Affiliates
Subsidiaries (2)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Cosmo Artificial Intelligence - Ai | Dublin, Ireland | 2015 | |
| Salix Pharmaceuticals (Dublin) | Dublin, Ireland | 2004 |
Cosmo Pharmaceuticals FAQs
-
When was Cosmo Pharmaceuticals founded?
Cosmo Pharmaceuticals was founded in 1997.
-
Where is Cosmo Pharmaceuticals headquartered?
Cosmo Pharmaceuticals is headquartered in Dublin, Ireland.
-
What is the size of Cosmo Pharmaceuticals?
Cosmo Pharmaceuticals has 339 total employees.
-
What industry is Cosmo Pharmaceuticals in?
Cosmo Pharmaceuticals’s primary industry is Pharmaceuticals.
-
Is Cosmo Pharmaceuticals a private or public company?
Cosmo Pharmaceuticals is a Public company.
-
What is Cosmo Pharmaceuticals’s stock symbol?
The ticker symbol for Cosmo Pharmaceuticals is COPN.
-
What is the current stock price of Cosmo Pharmaceuticals?
As of 14-Feb-2025 the stock price of Cosmo Pharmaceuticals is $71.16.
-
What is the current market cap of Cosmo Pharmaceuticals?
The current market capitalization of Cosmo Pharmaceuticals is $1.14B.
-
What is Cosmo Pharmaceuticals’s current revenue?
The trailing twelve month revenue for Cosmo Pharmaceuticals is $201M.
-
Who are Cosmo Pharmaceuticals’s competitors?
Spear Pharmaceuticals, Regeneron Pharmaceuticals, VYNE Therapeutics, Botanix Pharmaceuticals, and Pfizer Manufacturing Austria are some of the 26 competitors of Cosmo Pharmaceuticals.
-
What is Cosmo Pharmaceuticals’s annual earnings per share (EPS)?
Cosmo Pharmaceuticals’s EPS for 12 months was $4.67.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
